• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [21797 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2010     Committee for New Health Technology Assessment (CNHTA) [Hand transplantation]
2020     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Halcyon intensity-modulated beam conformal image-guided volumetric radiotherapy system for oncology treatment]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Hair micro transplant using follicular unit extraction technique for alopecia]
2009     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Hadrontherapy in the treatment of cancer]
2013     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Hadron therapy: proton and carbon ion therapy - a review of clinical evidence of efficacy, ongoing research and reimbursement]
2015     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Hadron therapy in children: evidence synthesis for 15 paediatric tumours. Report based on Belgian (KCE) HTA report]
2002     The Netherlands Organisation for Health Research and Development (ZonMw) [Gynecological cancer: diagnostic value of radiological tests]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guselkumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guselkumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guselkumab (plaque psoriasis) - Addendum to Commission A17-60]
2016     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides for the pharmacological treatment of STBBIs]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: wound care-assessment, management, and optimal treatment use]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: use of electrodiagnostic testing in the neurological investigation - electromyography and nerve conduction studies]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: urinary tract infection in people aged 14 and over - diagnostic guidelines, optimal use of 1st- and 2nd-line treatments and follow-up ]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: urethral discharge - diagnostic measures and pharmacological treatment]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: updated recommendations for adjusting antidiabetic medication in type 2 diabetes]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: update of the tool for choosing the dosage of monoclonal antibodies targeting PD 1 or PD-L1]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: update of the optimal usage guide on sexually transmitted and blood borne infections – confirmed Mycoplasma genitalium infection]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: unusual vaginal discharge - diagnostic measures and pharmacological treatment]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: type 2 diabetes screening and cardiovascular risk assessment]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: the management of myalgic encephalomyelitis / chronic fatigue syndrome]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: Syphilis - detection, diagnosis, optimal antibiotic use, and follow-up]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: optimal use of immunoglobulin in fertility, cardiology and other indications]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: optimal use of echocardiography in Québec- diagnosis and follow-up of chronic heart failure]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: optimal use of cardiac ultrasound in Québec - diagnosing patients with a murmur and monitoring patients with valve diseases (native and prosthetic valves)]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: methodological report in support of the reflection guide supporting clinical and organizational practices in rehabilitation services for young people with adjustment problems aged 10 or older]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: measurement and monitoring of total serum bilirubin in a newborn with signs suggestive of neonatal jaundice]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: intravenous iron therapy in adults]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: initiating pharmacological treatment for oropharyngeal mucositis in a patient receiving cancer therapy]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: initiate diagnostic measures in the presence of symptoms and signs suggestive of urinary tract infection (cystitis and pyelonephritis) and initiate first-line pharmacological treatment for cystitis in an individual 14 years of age and older]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: chronic obstructive pulmonary disease- detection, diagnosis, optimal use of medications and inhalation devices, and global management]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: asthma management in children and adults]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: acute exacerbation of chronic obstructive pulmonary disease -diagnostic approach, optimal use of treatments, and follow-up]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guides and glossary for hospital quality reports - Rapid report]
2011     Andalusian Health Technology Assessment Area (AETSA) [Guidelines to produce citizen-friendly health technology assessment reports]
1995     Basque Office for Health Technology Assessment (OSTEBA) [Guidelines for chronic leg ulcers in primary health care]
2005     Basque Office for Health Technology Assessment (OSTEBA) [Guidelines for assessing the impact of projects, programmes or non-health policies on health and well-being of individuals]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: urinary catheter placement in an adult with functional autonomy decline presenting with symptoms suggestive of acute urinary retention]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: standards for the management of acute ST-segment elevation myocardial infarction (STEMI) in Québec (update of April 2021)]
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: respiratory multiplex NAAT (8 or more targets)]
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: post-tick bite antibiotic prophylaxis to prevent Lyme disease, report in support of the knowledge transfer tools, the Québec’s national medical protocol and the collective prescription template]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: oral opioid agonists for the treatment of opioid use disorder]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: optimal use of immunoglobulins in infectious diseases]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: optimal use of immunoglobulin in solid organ transplantation]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: needs analysis grid for families followed by Integrated Perinatal and Early Childhood Services (SIPPE)]
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: managing the risk of suicide and self-harm among youths living in rehabilitation centres for young persons with adjustment problems]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: initiating pharmacotherapy for relapse prevention in a person with alcohol use disorder]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: initiating pharmacological treatment for clearing an occluded central venous access device (CVAD)]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: initiating diagnostic measures in a person with signs and symptoms suggestive of a urinary tract infection (cystitis or pyelonephritis) and initiating first-line pharmacological treatment for cystitis in an adult with functional autonomy decline]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: initiating blood work for the purpose of evaluating diagnosed or suspected alcohol use disorder]
2017     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: fibrinolysis in ST-segment elevation acute myocardial infarction]
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: autonomy in intellectually disabled young people aged 6 to 21 years]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: alcohol withdrawal and relapse prevention]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: administration of benzodiazepines or gabapentin prescribed via an individual prescription for alcohol withdrawal]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: assessment and risk management of severe neurological complications following mild traumatic brain injury]
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards, updated on May 4th 2020 : guide to preventing and treating chemotherapy or radiotherapy-induced nausea and vomiting in adults]
2018     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards, English version updated in June 2020: requirements relating to the institutions responsible for the operation of acute healthcare facilities designated within the Quebec trauma network]
2009     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis on depression]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for updating the DMP "Heart failure"]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for updating the DMP "Asthma"]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for the update of the DMP “type 1 diabetes”]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for the update of the DMP “Osteoporosis”]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for the update of the DMP “Depression”]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for the update of the DMP “Coronary heart disease”]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for the update of the DMP “Chronic back pain”]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for the update of the DMP "Rheumatoid Arthritis“]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for the update of the DMP "Breast cancer"]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for the DMP "type 2 diabetes"]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for the DMP "osteoporosis" - rapid report]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for the DMP "COPD"]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for obesity - children and adolescents]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for obesity - adults]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for a DMP "Depression"]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Guideline for the management of bipolar disorders in Catalonia]
2017     Andalusian Health Technology Assessment Area (AETSA) [Guideline for the elaboration of recommendations and appropriate use criteria in health technologies]
2016     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Guideline for the elaboration and adaptation of rapid health technology assessment reports]
2007     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Guided use of autologous chondrocyte implant: a five-year follow-up]
2015     Basque Office for Health Technology Assessment (OSTEBA) [Guide to evidence-based recommendations in the prevention and treatment of pressure ulcers in adults]
2014     Andalusian Health Technology Assessment Area (AETSA) [Guide to clinical practice of care in pregnancy and puerperium]
2017     Basque Office for Health Technology Assessment (OSTEBA) [Guide on Prader-Willi Syndrome. Guide to health personnel for the adequate knowledge and management of a rare disease called Prader-Willi Syndrome]
2016     Andalusian Health Technology Assessment Area (AETSA) [Guide for the preparation of evidence synthesis reports: medicines. Update]
2013     Andalusian Health Technology Assessment Area (AETSA) [Guide for the preparation of drug evaluation reports]
2013     Andalusian Health Technology Assessment Area (AETSA) [Guide for proper use of knee arthroplasty in patients with arthritis]
2013     Andalusian Health Technology Assessment Area (AETSA) [Guide for proper use of knee arthroplasty in patients with arthritis. Short version]
2013     Andalusian Health Technology Assessment Area (AETSA) [Guide for proper use of knee arthroplasty in patients with arthritis. Fast version]
2007     Andalusian Health Technology Assessment Area (AETSA) [Guide for decision-making on the introduction of genetic tests in the National Health System (GEN guide) Version 1]
2017     Basque Office for Health Technology Assessment (OSTEBA) [Guide for breastfeeding mother. Guide for women who wish to breastfeed or who breastfeed, as well as their partners and family]
2009     Basque Office for Health Technology Assessment (OSTEBA) [Group monitoring of psychotic patients in the public health network of the Basque Autonomous Community]
2011     The Netherlands Organisation for Health Research and Development (ZonMw) [Group medical appointments for neuromuscular patients]
2009     Finnish Office for Health Care Technology Assessment (Finohta) [Green laser treatment of hyperplasia of the prostate]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Glycopyrronium bromide (sialorrhoea) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Glycopyrronium (axillary hyperhidrosis) - Benefit assessment according to §35a Social Code Book V]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Glycerol phenylbutyrate (urea-cycle disorders) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Glycerol phenylbutyrate (urea cycle disorders) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Glucocorticosteroid intravitreal implants in posterior retina diseases]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Glucarpidase (toxic MTX plasma concentrations) - Assessment according to §35a SGB V (1), Sentence 11]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Glofitamab (diffuse large B-cell lymphoma) – Assessment according to § 35a Social Code Book (SGB) V (1) Sentence 11]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Global postural re-education in spine diseases]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Global postural re-education (RPG®) in spine conditions]
2008     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Glitazones in the treatment of diabetes mellitus type 2]